Oxidized LDL reduces monocyte CCR2 expression through pathways involving peroxisome proliferator-activated receptor γ

Journal of Clinical Investigation

Volumn 106, Issue 6, 2000, Pages 793-802

  Han, Ki Hoon ^a   Chang, Mi Kyung ^a   Boullier, Agnes ^a   Green, Simone R ^a   Li, Andrew ^a   Glass, Christopher K ^a   Quehenberger, Oswald ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR2; LOW DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; FLOW CYTOMETRY; HUMAN; INFLAMMATION; MONOCYTE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 0001538199     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI10052     Document Type: Article

References (57)

1. Gerrity, R.G. 1981. The role of the monocyte in atherogenesis. I. Transition of blood-borne monocytes into foam cells in fatty lesions. Am. J. Pathol. 103:181-190.
2. Valente, A.J., Rozek, M.M., Sprague, E.A., and Schwartz, C.J. 1992. Mechanisms in intimal monocyte-macrophage recruitment. A special role for monocyte chemotactic protein-1. Circulation. 86:11120-11125.
3. Rollins, B.J., Yoshimura, T., Leonard, E.J., and Pober, J.S. 1990. Cyrokine-activated human endothelial cells synthesize and secrete a monocyte chemoattractant, MCP-1/JE. Am. J. Pathol. 136:1229-1233.
4. Shyy, Y.J., et al. 1993. Human monocyte colony-stimulating factor stimulates the gene expression of monocyte chemotactic protein-1 and increases the adhesion of monocytes to endothelial monolayers. J. Clin. Invest. 92:1745-1751.
5. Brown, Z., et al. 1994. Chemokine gene expression and secretion by cytokine-activated human microvascular endothelial cells: differential regulation of monocyte chemoattractant protein-1 and interleukin-8 in response to interferon-gamma. Am. J. Pathol. 145:913-921.
6. Wenzel, U.O., et al. 1995. Thrombin regulates expression of monocyte chemoattractant protein-1 in vascular smooth muscle cells. Circ. Res. 77:503-509.
7. Cushing, S.D., et al. 1990. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc. Natl. Acad. Sci. USA. 87:5134 -5138.
8. Nelken, N.A., Coughlin, S.R., Gordon, D., and Wilcox, J.N. 1991. Monocytechemoattractant protein-1 in human atheromatous plaques. J. Clin. Invest. 88:1121-1127.
9. Yla-Herttuala, S., et al. 1991. Impression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc. Natl. Acad. Sci. USA. 88:5252-5256.
10. Gu, L., et al. 1998. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol. Cell. 2:275-281.
11. Gosling, J., et al. 1999. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J. Clin. Invest. 103:773-778.
12. Aiello, R.J., et al. 1999. Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 19:1518-1525.
13. Rollins, B.J., Morrison, E.D., and Stiles, C.D. 1988. Cloning and expression of JE, a gene inducible by platelet-derived growth factor and whose product has cytokine-like properties. Proc. Natl. Acad. Sci. USA. 85:3738-3742.
14. Yoshimura, T., et al. 1989. Purification and amino acid analysis of two human glioma-derived monocyte chemoattractants. J. Exp. Med. 169:1449-1459.
15. Charo, I.F., et al. 1994. Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails. Proc. Natl. Acad. Sci. USA. 91:2752-2756.
16. Mackay, C.R. 1996. Chemokine receptors and T cell chemotaxis. J. Exp. Med. 184:799-802.
17. Monteclaro, E.S., and Charo, I.F. 1997. The amino-terminal domain of CCR2 is both necessary and sufficient for high affinity binding of monocyte chemoattractant protein I. Receptor activation by a pseudo-tethered ligand. J. Biol Chem. 272:23186-23190.
18. Han, K.H., Green, S.R., Tangirala, R.K., Tanaka, S., and Quehenberger, O. 1999. Role of the first extracellular loop in the functional activation of CCR2: the first extracellular loop contains distinct domains necessary for both agonist binding and transmembrane signaling. J. Biol. Chem. 274:32055-32062.
19. Kuziel, W.A., et al. 1997. Severe reduction in leukocyte adhesion and monocyte extravasation in mice deficient in CC chemokine receptor 2. Proc. Natl. Acad. Sci. USA. 94:12053-12058.
20. Boring, L., et al. 1997. Impaired monocyte migration and reduced type 1 (Th 1) cytokine responses in C-C chemokine receptor 2 knockout mice. J. Clin. Invest. 100:2552-2561.
21. Boring, L., Gosling, J., Cleary, M., and Charo, I.F. 1998. Decreased lesion formation in CCR2 mice reveals a role for chemokines in the initiation of atherosclerosis. Nature. 394:894-897.
22. Han, K.H., Han, K.O., Green, S.R., and Quehenberger, O. 1999. Expression of the monocyte chemoattractant protein-1 receptor CCR2 is increased in hypercholesterolemia: differential effects of plasma lipoproteins on monocyte function. J. Lipid Res. 40:1053-1063.
23. Steinberg, D., Parthasarathy, S., Carew, T.E., Khoo, J.C., and Witztum, J.L. 1989. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 320:915-924.
24. Steinberg, D. 1997. Low density lipoprotein oxidation and its pathobiological significance. J. Biol. Chem. 272:20963-20966.
25. Han, K.H., Tangirala, R.K., Green, S.R., and Quehenberger, O. 1998. Chemokine receptor CCR2 expression and monocyte chemoattractant protein-1-mediated chemotaxis in human monocytes. A regulatory role for plasma LDL. Arterioscler Thromb. Vasc. Biol. 18:1983-1991.
26. Tontonoz, P., Hu, H., Graves, R.A., Budavari, A.I., and Spiegelman, B.M. 1994. mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev. 8:1224-1234.
27. Chawla, A., Schwarz, E.J., Dimaculangan, D.D., and Lazar, M.A. 1994. Peroxisome proliferator-activated receptor (PPAR) gamma:adipose-pre-dominant expression and induction early in adipocyte differentiation. Endocrinology. 135:798-800.
28. Lehmann, J.M., et al. 1995. An antidiabetic rhiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem. 270:12953-12956.
29. Willson, T.M., et al. 1996. The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. J. Med. Chem. 39:665-668.
30. Tontonoz, P., Nagy, L., Alvarez, J.G., Thomazy, V.A., and Evans, R.M. 1998. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell. 93:241-252.
31. Ricote, M., et al. 1998. Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc. Natl. Acad. Sci. USA. 95:7614-7619.
32. Ricote, M., Huang, J.T., Welch, J.S., and Glass, C.K. 1999. The peroxisome proliferator-activated receptor(PPARgamma) as a regulator of monocyte/macrophage function. J. Leukoc. Biol. 66:733-739.
33. Havel, R.J., Eder, H.A., and Bragdon, J.H. 1955. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J. Clin. Invest. 34:1345-1353.
34. Lowry, D.H., Rosebrough, N.J., Farr, A.L., and Randall, R.J. 1951. Protein measurement with the folin phenol reagent. J. Biol. Chem. 193:265-275.
35. Conti, M., Morand, P.C., Levillain, P., and Lemonnier, A. 1991. Improved fluorometric determination of malonaldehyde. Clin. Chem. 37:1273-1275.
36. Parthasarathy, S., Fong, L.G., Otero, D., and Steinberg, D. 1987. Recognition of solubilized apoproteins from delipidated, oxidized low density lipoprotein (LDL) by the acetyl-LDL receptor. Proc. Natl. Acad. Sci. USA. 84:537-540.
37. Terpstra, V., Bird, D.A., and Steinberg, D. 1998. Evidence that the lipid moiety of oxidized low density lipoprotein plays a role in its interaction with macrophage receptors. Proc. Natl. Acad. Sci. USA. 95:1806-1811.
38. Marinetti, G. 1962. Chromatographic separation, identification, and analysis of phosphatides. J. Lipid Res. 3:1-20.
39. Reaven, P., et al. 1993. Effects of oleate-rich and linoleate-rich diets on the susceptibility of low density lipoprotein to oxidative modification in mildly hypercholesterolemic subjects. J. Clin. Invest. 91:668-676.
40. Quehenberger, O., Jurgens, G., Zadravec, S., and Esterbauer, H. 1988. Oxidation of human low density lipoprotein initiated by copper(II)chloride. Basic Life Sci. 49:387-390.
41. Chomczynski, P., and Sacchi, N. 1987. Single-step method of RNA isolation by acid guamdinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:156-159.
42. Tangirala, R.K., Murao, K., and Quehenberger, O. 1997. Regulation of expression of the human monocyte chemotactic prorein-1 receptor (hCCR2) by cytokines. J Biol. Chem. 272:8050-8056.
43. Watson, A.D., et al. 1997. Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo. J. Biol. Chem. 272:13597-13607.
44. Hörkkö, S., et al. 1999. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phosphohpid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J. Clin. Invest. 103:117-128.
45. Boullier, A., et al. 2000. The binding of oxidized low density lipoprotein to mouse CD36 is mediated in part by oxidized phospholipids that are associated with both the lipid and protein moieties of the lipoprotein. J. Biol. Chem. 275:9163-9169.
46. Nagy, L., Tontonoz, P., Alvarez, J.G., Chen, H., and Evans, R.M. 1998. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell. 93:229-240.
47. Huang, J.T., et al. 1999. Interleukin-4-dependent production of PPARgamma ligands in macrophages by 12/15-lipoxygenase. Nature. 400:378-382.
48. Nolte, R.T., et al. 1998. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature. 395:137-143.
49. Yamada, Y., Doi, T., Hamakubo, T., and Kodama, T. 1998. Scavenger receptor family proteins: roles for atherosclerosis, host defense and disorders of the central nervous system. Cell. Mol. Life Sci. 54:628-640.
50. Forman, B.M., Chen, J., and Evans, R.M. 1997. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc. Natl. Acad. Sci. USA. 94:4312-4317.
51. Benz, D,J., et al. 1995. Enhanced levels of lipoperoxides in low density lipoprotein incubated with murine fibroblast expressing high levels of human 15-lipoxygenase. J. Biol. Chem. 270:5191-5197.
52. Folcik, V.A., Niva:-Aristy, R.A., Krajewski, L.P., and Cathcart, M.K. 1995. Lipoxygenase contributes to the oxidation of lipids in human atherosclerotic plaques. J. Clin. Invest. 96:504-510.
53. Yamashita, H., Nakamura, A., Noguchi, N., Niki, E., and Keuhn, H. 1999. Oxidation of low density lipoprotein and plasma by 15-lipoxygenase and free radicals. FEBS Lett. 445:287-290.
54. Zhu, L., Bisgaier, C.L., Aviram, M., and Newton, R.S. 1999. 9-cis retinoic acid induces monocyte chemoattractant protein-1 secretion in human monocytic THP-1 cells. Arterioscler. Thromb. Vasc. Biol. 19:2105-2111.
55. Nozaki, S., et al. 1995. Reduced uptake of oxidized low density lipoproteins in monocyte-derived macrophages from CD36-deficient subjects. J. Clin. Invest. 96:1859-1865.
56. Febbraio, M., et al. 1999. A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism. J. Biol. Chem. 274:19055-19062.
57. Greenwalt, D.E., et al. 1992. Membrane glycoprotein CD36: a review of its roles in adherence, signal transduction, and transfusion medicine. Blood. 80:1105-1115.